<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 7; Issue 4</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(Jul-Aug, 2026)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Esketamine for The Treatment of Complex PTSD and Treatment-Resistant Depression: A Case Report</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>11</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Olivola</FirstName>
          <LastName>Miriam</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Mazzoni</FirstName>
          <LastName>Filippo</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Dalò</FirstName>
          <LastName>Valentina</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Grechi</FirstName>
          <LastName>Edoardo</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Brondino</FirstName>
          <LastName>Natascia</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Dell’Osso Bernardo</FirstName>
          <LastName>Maria</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Migliarese</FirstName>
          <LastName>Giovanni</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Complex post-traumatic stress disorder (C-PTSD) frequently co-occurs with treatment-resistant depression (TRD), resulting in severe functional impairment, persistent suicidal ideation, and poor response to conventional treatments. We report the case of a 30-year-old woman with recurrent major depressive disorder, Complex PTSD, and borderline personality disorder, characterized by childhood neglect, sexual abuse, emotional dysregulation, recurrent self-harm, multiple psychiatric hospitalizations, and inadequate response to several pharmacological treatments. Because of persistent depressive symptoms and chronic suicidal ideation, intranasal esketamine was initiated at 56 mg for the first session and increased to 84 mg thereafter, alongside ongoing psychopharmacological treatment. Clinical outcomes were assessed using the Montgomery-__ampersandsignAring;sberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), and Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) over a 12-month follow-up. Sustained clinical improvement was observed, with MADRS decreasing from 36 to 4, HAM-A from 38 to 7, and CAPS-5 from 55 to 15, accompanied by complete remission of suicidal ideation. Improvements also involved core trauma-related symptoms, including intrusive recollections, hyperarousal, emotional dysregulation, and avoidance behaviors. This case suggests that intranasal esketamine may represent a promising therapeutic option for patients with treatment-resistant depression and comorbid Complex PTSD, producing sustained benefits across depressive, anxiety, and trauma-related symptom domains. Although limited by the single-case design, these findings support further investigation of esketamine in complex trauma-related psychopathology.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Esketamine,Treatment-Resistant Depression,Complex PTSD,Borderline Personality Disorder,Suicidal Ideation,Trauma</Keywords>
      <URLs>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=16296&amp;title=Esketamine for The Treatment of Complex PTSD and Treatment-Resistant Depression: A Case Report</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders. 5th edn. Arlington, VA: American Psychiatric Publishing.&#13;
&#13;
Bedard-Gilligan M, Duax Jakob JM, Doane LS, Jaeger J, Eftekhari A, Feeny N, Zoellner LA. An Investigation of Depression, Trauma History, and Symptom Severity in Individuals Enrolled in a Treatment Trial for Chronic PTSD. J Clin Psychol 2015; 71: 725-740.&#13;
&#13;
Duek O, Li Y, Kelmendi B, Amen S, Gordon C, Milne M, Krystal JH, Levy I, Harpaz-Rotem I. Modulating amygdala activation to traumatic memories with a single ketamine infusion. Medrxiv 2021; 9: 2021-2107.&#13;
&#13;
Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016; 22: 238-249.&#13;
&#13;
Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, Kirkwood K, Aan Het Rot M, Lapidus KA, Wan LB, Iosifescu D, Charney DS. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014; 71: 681-688.&#13;
&#13;
Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Bevilacqua L, Glasgow AM, Brallier J, Pietrzak RH, Murrough JW, Charney DS. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry 2021; 178: 193-202.&#13;
&#13;
First MB. Structured clinical interview for DSM-IV axis II personality disorders, (SCID-II). (Washington, DC: American Psychiatric Press). 1997.&#13;
&#13;
HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55.&#13;
&#13;
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.&#13;
&#13;
Olivola M, Mazzoni F, Tarantino B, Guffanti A, Marcatili M, Macellaro M, Girone N, Martiadis V, Raffone F, Prodi T, Brondino N, Martinotti G, Clerici M, Anniverno R, Delland;#39;Osso B. Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality. Front Psychiatry 2026; 16: 1736114.&#13;
&#13;
Oquendo M, Brent DA, Birmaher B, Greenhill L, Kolko D, Stanley B, Zelazny J, Burke AK, Firinciogullari S, Ellis SP, Mann JJ. Posttraumatic stress disorder comorbid with major depression: factors mediating the association with suicidal behavior. Am J Psychiatry 2005; 162: 560-566.&#13;
&#13;
Raab PA, Mackintosh MA, Gros DF, Morland LA. Impact of comorbid depression on quality of life in male combat Veterans with posttraumatic stress disorder. J Rehabil Res Dev 2015; 52: 563-576.&#13;
&#13;
Raffone F, Cattaneo CI, Pessina E, Martini A, Martiadis V. Toward Integrating Intranasal Esketamine with Traumatic-Memory Psychotherapy in Treatment-Resistant Depression: A Narrative Review and Feasibility-Oriented Protocol Proposal. Behav Sci (Basel) 2026a; 16: 771.&#13;
&#13;
Raffone F, Mazzoni F, De Ciechi A, Girone N, Macellaro M, Martinotti G, Delland;rsquo;Osso B, Olivola M, Martiadis V. Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: a real-world longitudinal study of suicidal ideation and self-harm. Asian J Psychiatr 2026b: 104983.&#13;
&#13;
Rothand;auml;rmel M, Mekaoui L, Kazour F, Herrero M, Beetz-Lobono EM, Lengvenyte A, Holtzmann J, Raynaud P, Cuenca M, Bulteau S, et al. Intranasal esketamine in treatment-resistant depression with comorbid PTSD: an open-label pilot study. Eur J Psychotraumatol 2022.&#13;
&#13;
Rothand;auml;rmel M, Mekaoui L, Kazour F, Herrero M, Beetz-Lobono EM, Lengvenyte A, Holtzmann J, Raynaud P, Cuenca M, Bulteau S, De Maricourt P. Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series. Eur J Psychotraumatol 2026; 17: 2609425.&#13;
&#13;
Rytwinski NK, Scur MD, Feeny NC, Youngstrom EA. The coand;#8208;occurrence of major depressive disorder among individuals with posttraumatic stress disorder: A metaand;#8208;analysis. J Trauma Stress 2013; 26: 299-309.&#13;
&#13;
Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess 2018; 30: 383-395.&#13;
&#13;
World Health Organization (2019) International Classification of Diseases 11th Revision (ICD-11). Geneva: World Health Organization.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>